The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Celgene
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.
Celgene and Novartis are among the companies accused of thwarting generic drugs.
Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.
With Juno, Celgene will gain research into a novel class of therapies known as CAR-T.